Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.
Cytek Biosciences, Inc. reports recurring developments in cell analysis instruments, reagents, services, and financial performance. The company uses patented Full Spectrum Profiling™ (FSP®) technology to analyze fluorescence signals in flow cytometry and related cell analysis workflows.
News about Cytek Biosciences commonly covers earnings releases, revenue trends, recurring service and reagent revenue, instrument placements, product platforms such as Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS, Cytek Aurora™ Evo, Cytek Orion™, ESP™ detection technology, and Amnis® and Guava® products, as well as investor conference participation and business outlook updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cytek Biosciences (Nasdaq: CTKB) announced it will release its first quarter 2023 financial results after the market closes on May 9, 2023. A conference call, starting at 1:30 PM PT / 4:30 PM ET, will follow to discuss these results along with business developments and future outlook. The call can be accessed via the company's investor webpage. Cytek specializes in cell analysis tools, leveraging its Full Spectrum Profiling™ technology to enhance precision and multiplexing. With the recent acquisition of DiaSorin’s Flow Cytometry & Imaging business unit, it added Amnis® and Guava® flow cytometers to its offerings, strengthening its product lineup. Most of Cytek's products are designated for research use only, with limited availability for clinical use in regions with regulatory approvals.